Jul 3, 2025, 01:00 AM by User Not Found

Bio-IT World | In a commentary published last week in Cell, researchers from the Arc Institute introduced the “Virtual Cell Challenge,” a public competition with a grand prize worth $100,000 for the machine learning model that best predicts how cells will respond to genetic perturbations.

Jul 2, 2025, 08:36 AM by

Femasys has received regulatory approvals in Australia and New Zealand for its innovative infertility solutions—FemaSeed®, a first-line, intratubal insemination treatment, and FemVue®, a diagnostic tool for assessing fallopian tube patency. These approvals mark a strategic expansion of the company’s global footprint and further validate its mission to offer more accessible, less invasive, and cost-effective fertility care. With FemaSeed shown to more than double pregnancy rates over traditional IUI in clinical trials, and FemVue enabling real-time fertility diagnostics in-office, this milestone offers new hope to patients facing infertility and strengthens Femasys’ commercial potential in international markets.

Jul 2, 2025, 08:36 AM by

Jul 2, 2025, 08:36 AM by

Jul 2, 2025, 08:35 AM by

Gene by Gene Supports Landmark Pharmacogenomics Trial to Personalize Prescribing in NHS Scotland

Jul 2, 2025, 01:00 AM by User Not Found

Bio-IT World | Consumer genomics pioneer 23andMe will be returning to its co-founder and former CEO as Anne Wojcicki’s TTAM Research Institute outbids Regeneron to buy 23andMe out of bankruptcy—as long as no more state attorneys general object. The current iteration of the sale is expected to close on July 8.

Jul 1, 2025, 08:19 AM by

Oxford-based Ochre Bio, a biotechnology company developing RNA therapeutics for chronic liver disease, has appointed Dr Quin Wills as CEO.

Jul 1, 2025, 08:19 AM by

Takara Bio Europe is pleased to announce it has entered into a distribution agreement with MACHEREY-NAGEL to expand access to high-quality bioanalysis products.

Jul 1, 2025, 08:19 AM by

PharmaForceIQ has announced a period of significant growth as it goes beyond omnichannel to optichannel campaign solutions. The company is the fastest growing independent provider of precision customer engagement technologies for the Life Science industry, and it has experienced a multifold increase in average contract value in the past year. In one client, the company expanded from a pilot campaign for one specialty brand to their entire specialty pharmaceutical portfolio in only 7 months. PharmaForceIQ also has a 100% client renewal rate – demonstrating that its data-driven strategies deliver unmatched efficiency and tangible results

Jul 1, 2025, 08:19 AM by

Jul 1, 2025, 01:00 AM by User Not Found

Bio-IT World | In Stanford University's engineering labs, Tom Soh has been wrestling with a paradox that has plagued medicine for decades. While modern jet engines generate terabytes of data every hour to prevent catastrophic failures, the human body gets monitored only during annual checkups or after something has already gone wrong.

Jun 30, 2025, 08:12 AM by

Rewriting the Timeline of Detection: Linus Health's Digital Platform Uncovers the Earliest Signs of Cognitive Decline

Jun 30, 2025, 08:12 AM by

Laverock Therapeutics closes additional seed funding round, bringing total raised to more than £20m, and announces key data

Jun 27, 2025, 08:17 AM by

Baylor Genetics, a leading clinical diagnostic laboratory at the forefront of genetic testing, today announced its support for the American Academy of Pediatrics’ (AAP) updated guidance recommending whole genome and whole exome sequencing as first-tier tests. Baylor Genetics has long recognized the value of these tests, and offers a comprehensive, structured framework to help pediatricians promptly identify potential genetic causes in children presenting with global developmental delay (GDD) or intellectual disability (ID). This milestone empowers pediatricians, supported by genetics professionals, with access to earlier and more comprehensive insights that guide clinical decisions for patients and their families, marking a critical step toward faster diagnoses and improved outcomes.

Jun 26, 2025, 07:59 AM by

The project aims at translational mechanistic modeling of antibodies to predict human pharmacokinetics and target occupancy in cerebrospinal fluid

Jun 26, 2025, 07:59 AM by

Alithea Genomics has announced the commercial launch of MERCURIUS™ FLASH-seq, a next-generation library preparation kit for full-length single-cell RNA sequencing.

Jun 26, 2025, 07:59 AM by

ISM3412 was designed with the support of Chemistry42, Insilico’s proprietary generative chemistry engine, for the treatment of locally advanced and metastatic solid tumors. The Phase I study of ISM3412 is currently recruiting in multiple sites across the United States and China, aiming to evaluate the safety, tolerability, PK/PD profiles and preliminary efficacy in patients.

Jun 26, 2025, 01:00 AM by User Not Found

Bio-IT World | The UK's National Health Service is pioneering a new approach to precision medicine through pharmacogenomic testing that could transform how doctors prescribe medications and significantly reduce healthcare costs. Early results from the NHS PROGRESS trial suggest that genetic testing can guide prescribing decisions for nearly all patients, with one in four participants having their prescriptions adjusted for safer or more effective treatment.

Jun 25, 2025, 08:26 AM by

Jun 25, 2025, 08:26 AM by

AMP recently published a new report with 12 best practice recommendations focused on the design and validation of clinical HRD assays. To develop these recommendations, AMP assembled an expert panel that included organizational representation from ACCC, ASCO, and the CAP.